-
公开(公告)号:WO2007142323A1
公开(公告)日:2007-12-13
申请号:PCT/JP2007/061598
申请日:2007-06-08
IPC: C07D401/04 , A61K31/416 , A61K31/4439 , A61P1/00 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/06 , A61P15/06 , A61P19/10 , A61P25/28 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/18 , A61P35/00 , A61P37/06 , A61P43/00 , C07D231/56
CPC classification number: C07D231/56 , C07D401/04
Abstract: The present invention aims to produce a novel pharmaceutically useful indazole derivative having a spiro ring structure in a side chain, and to find a novel pharmacological action of the derivative. Specifically disclosed is a compound represented by the general formula (I) below, which has excellent Rho kinase inhibitory activity. In the formula below, ring X represents a benzene ring or a pyridine ring; R 1 and R 2 independently represent a halogen, H, OH, alkoxy, cycloalkyloxy, aryloxy, alkyl, cycloalkyl or the like; R 3 represents a halogen, H or the like; R 4 and R 5 independently represent a halogen, H or the like; R 6 and R 7 independently represent H, an alkyl or the like; and m, n, p and q independently represent an integer of 0-3. In this connection, each group may have a substituent.
Abstract translation: 本发明旨在制备在侧链具有螺环结构的新颖的药学上有用的吲唑衍生物,并找到该衍生物的新的药理作用。 具体公开了下述通式(I)表示的化合物,其具有优异的Rho激酶抑制活性。 在下式中,环X表示苯环或吡啶环; R 1和R 2独立地表示卤素,H,OH,烷氧基,环烷氧基,芳氧基,烷基,环烷基等; R 3表示卤素,H等; R 4和R 5独立地表示卤素,H等; R 6和R 7独立地表示H,烷基等; m,n,p和q独立地表示0-3的整数。 在这方面,每个基团可以具有取代基。
-
公开(公告)号:JP6176258B2
公开(公告)日:2017-08-09
申请号:JP2014554626
申请日:2013-12-27
Applicant: 宇部興産株式会社
IPC: A61P37/02 , A61P29/00 , A61P25/00 , A61P13/00 , A61P35/00 , A61K31/381 , C07D409/04 , A61K31/4436 , C07D417/12 , A61K31/427 , C07D409/14 , C07D333/36
CPC classification number: C07D333/36 , A61K31/381 , A61K31/427 , A61K31/443 , C07D409/04 , C07D409/12 , C07D409/14 , C07D417/12
-
3.
公开(公告)号:JP5824872B2
公开(公告)日:2015-12-02
申请号:JP2011118032
申请日:2011-05-26
Applicant: 宇部興産株式会社
IPC: A61P39/06 , A61K31/4439 , A61P9/10 , A61P9/06 , A61P13/12 , A61P9/12 , A61P3/06 , A61P25/28 , A61P25/16 , A61P25/00 , A61P1/04 , A61P1/08 , A61P3/10 , A61P1/18 , A61P1/16 , A61P11/00 , A61P11/06 , A61P5/00 , A61P31/04 , A61P29/00 , A61P37/00 , A61P17/04 , A61P17/00 , A61P17/06 , A61P17/02 , A61P31/22 , A61P31/18 , A61P35/00 , A61P27/02 , A61P27/12 , C07D401/04
CPC classification number: C07D401/14 , C07D401/04 , C07D401/10 , C07D405/14
-
-
公开(公告)号:WO2005035506A1
公开(公告)日:2005-04-21
申请号:PCT/JP2004/015663
申请日:2004-10-15
IPC: C07D231/56
CPC classification number: C07D231/56 , C07D401/04 , C07D403/04 , C07D413/04
Abstract: To prepare a novel indazole derivative useful as a medicine and to find out a new pharmacological activity of the derivative. The compound is represented by the general formula [I] and has excellent Rho-kinase inhibitory activity. In the formula, ring X is a benzene ring or pyridine ring; R and R each is hydrogen or alkyl; R and R each is halogeno, hydrogen, OH, alkoxy, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, aryloxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, carboxy, hydrocarbonyl, alkylcarbonyl, etc.; and R is halogeno, hydrogen, OH, alkoxy, aryloxy, alkyl, or aryl. These groups may be substituted.
Abstract translation: 制备可用作药物的新型吲唑衍生物,并找出衍生物的新药理活性。 该化合物由通式[I]表示,具有优异的Rho-激酶抑制活性。 在该式中,环X为苯环或吡啶环; R 1和R 2各自为氢或烷基; R 3和R 4各自为卤代,氢,OH,烷氧基,烯氧基,炔氧基,环烷氧基,环烯氧基,芳氧基,烷基,烯基,炔基,环烷基,环烯基,芳基,羧基,烃基,烷基羰基等。 R 5为卤代,氢,OH,烷氧基,芳氧基,烷基或芳基。 这些基团可以被取代。
-
公开(公告)号:WO2005035503A1
公开(公告)日:2005-04-21
申请号:PCT/JP2004/015657
申请日:2004-10-15
IPC: C07D217/02
CPC classification number: C07D401/04 , A61K31/472 , A61K31/4725 , C07D217/02 , C07D217/22 , C07D217/24 , C07D217/26 , C07D413/04
Abstract: To prepare a novel isoquinoline derivative useful as a subject medicine and to find out a new pharmacological activity of the derivative. The compound is represented by the general formula [I] and has excellent Rho-kinase inhibitory activity. In the formula, X represents a benzene ring or monocyclic aromatic heterocycle; Y represents the general formula (a), (b), (c), (d), (e), or (f); R and R each represents hydrogen or alkyl; and R and R each represents halogeno, hydrogen, OH, alkoxy, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, aryloxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, carboxy, hydrocarbonyl, alkylcarbonyl, arylcarbonyl, amino, alkylamino, arylamino, mercapto, alkylthio, arylthio, etc., provided that the groups may be substituted.
Abstract translation: 制备用作主题药物的新型异喹啉衍生物,并找出衍生物的新药理活性。 该化合物由通式[I]表示,具有优异的Rho-激酶抑制活性。 在该式中,X表示苯环或单环芳族杂环; Y代表通式(a),(b),(c),(d),(e)或(f); R 1和R 2各自表示氢或烷基; R 3和R 4各自表示卤代,氢,OH,烷氧基,烯氧基,炔氧基,环烷氧基,环烯氧基,芳氧基,烷基,烯基,炔基,环烷基,环烯基,芳基,羧基,烃基,烷基羰基,芳基羰基, 氨基,烷基氨基,芳基氨基,巯基,烷硫基,芳硫基等,条件是这些基团可以被取代。
-
公开(公告)号:JP6569792B2
公开(公告)日:2019-09-04
申请号:JP2018188246
申请日:2018-10-03
Applicant: 宇部興産株式会社
IPC: C07D409/04 , C07D417/12 , C07D409/14 , A61K31/381 , A61K31/4436 , A61K31/425 , A61P1/16 , C07D333/36
-
公开(公告)号:JP2019014739A
公开(公告)日:2019-01-31
申请号:JP2018188246
申请日:2018-10-03
Applicant: 宇部興産株式会社
IPC: C07D409/04 , C07D417/12 , A61K31/381 , A61K31/4436 , A61K31/425 , A61P43/00 , A61P37/02 , A61P29/00 , A61P25/00 , A61P25/02 , A61P13/00 , A61P35/00 , C07D333/36
Abstract: 【課題】強力なLPA受容体拮抗作用を有する、新規なα位ハロゲン置換チオフェン化合物の提供。 【解決手段】式(I)で表される化合物又はその塩。 [Aはフェニル環、チオフェン環又はイソチアゾール環;R 1 はハロゲン原子又はC 1 −C 3 アルキル基;R 2 はH又はC 1 −C 6 アルキル基;pは0−5;VはCR 3 (R 3 はH、アミノ基、NO 2 又はC 1 −C 3 アルコキシ基)又はN;Xはハロゲン原子。] 【選択図】なし
-
公开(公告)号:JP6414286B2
公开(公告)日:2018-10-31
申请号:JP2017135811
申请日:2017-07-11
Applicant: 宇部興産株式会社
IPC: C07D409/04 , C07D409/14 , C07D417/12 , C07F5/02 , C07D333/36
CPC classification number: C07D333/36 , A61K31/381 , A61K31/427 , A61K31/443 , A61P13/00 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/00 , A61P43/00 , C07D409/04 , C07D409/12 , C07D409/14 , C07D417/12
-
公开(公告)号:JP2017214410A
公开(公告)日:2017-12-07
申请号:JP2017135811
申请日:2017-07-11
Applicant: 宇部興産株式会社
IPC: A61K31/381 , A61K31/427 , A61K31/443 , A61P13/00 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/02 , A61P43/00 , C07D409/04 , C07D409/14 , C07D417/12 , C07D333/36
CPC classification number: C07D333/36 , A61K31/381 , A61K31/427 , A61K31/443 , C07D409/04 , C07D409/12 , C07D409/14 , C07D417/12
Abstract: 【課題】強力なLPA受容体拮抗作用を有し、医薬として有用な新規なα位ハロゲン置換チオフェン化合物、又は、その薬理上許容される塩の提供。 【解決手段】式(I)で表される化合物、又は、その塩。 (Aはフェニル、チオフェン又はイソチアゾール;R 1 は各々独立にハロゲン又はC 1 −C 3 のアルキル;R 2 はH又はC 1 − 6 のアルキル;pは0〜5の整数;VはCR 3 又はN;R 3 はH、アミノ、ニトロ、C 1 − 3 のアルコキシ;Xはハロゲン) 【選択図】なし
-
-
-
-
-
-
-
-
-